Springer Nature [academic journals on nature.com], Prostate Cancer and Prostatic Diseases, 4(16), p. 323-327, 2013
DOI: 10.1038/pcan.2013.20
Full text: Download
BACKGROUND: About 20% of patients with prostate cancer have an ECOG performance status (PS) >= 2 at diagnosis. We investigate if current treatment options for castration-resistant prostate cancer (CRPC) may decrease the risk of death even in patients with ECOG PS of 2. METHODS: PubMed was reviewed for phase III randomized trials in patients with CRPC progressed after docetaxel chemotherapy. Characteristics of each study and the relative hazard ratio (HR) for overall survival and 95% confidence interval (CI) were collected. Summary HR was calculated using random-or fixed-effects models depending on the heterogeneity of included studies. RESULTS: A total of 3,149 patients was available for meta-analysis. In the overall population, the experimental treatments decrease the risk of death by 31% (HR = 0.69; 95% CI: 0.63-0.76; P